Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens-Reference-Cited by-同舟云学术

Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens

Published:2022-02-17 Issue:6 Volume:65 Page:4481-4495
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ma Zhenkun¹^ORCID,He Shijie¹,Yuan Ying¹,Zhuang Zhijun¹,Liu Yu¹,Wang Huan¹,Chen Jing¹,Xu Xiangyi¹,Ding Charles¹,Molodtsov Vadim²,Lin Wei²^ORCID,Robertson Gregory T.³,Weiss William J.⁴,Pulse Mark⁴,Nguyen Phung⁴,Duncan Leonard⁵,Doyle Timothy⁵,Ebright Richard H.²,Lynch Anthony Simon¹

Affiliation:

1. TenNor Therapeutics Ltd, 218 Xinghu Street, Suzhou Industrial Park, Suzhou 215123, China

2. Waksman Institute and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, New Jersey 08854, United States

3. Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, 80523-1682, United States

4. HSC College of Pharmacy, University of North Texas, Fort Worth, Texas 76107, United States

5. JMI Laboratories, North Liberty, Iowa 52317, United States

Funder

Ministry of Science and Technology of the People's Republic of China

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c02045

Reference51 articles.

1. World Health Organization. Global shortage of innovative antibiotics fuels emergence and spread of drug-resistance; WHO: Geneva, 2021. https://www.who.int/news/item/15-04-2021-global-shortage-of-innovative-antibiotics-fuels-emergence-and-spread-of-drug-resistance (accessed 2022-01-12).

2. U.S. Department of Health and Human Services, CDC. Antibiotic resistance threats in the United States; CDC: Atlanta, GA, 2019.

3. The Pew Charitable Trusts. Tracking the global pipeline of antibiotics in development; The Pew Charitable Trusts: Philadelphia, PA, 2021. https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2019/03/tracking-the-global-pipeline-of-antibiotics-in-development (accessed 2022-01-12).

4. Helicobacter pylori treatment in the post-antibiotics era—searching for new drug targets

5. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Update on the Clinical Pipelines of New Antibacterial Drugs Developed in China;Engineering;2024-07

2. Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials;The Lancet Infectious Diseases;2024-06

3. A novel dual targeted antibacterial agent for Helicobacter pylori;The Lancet Infectious Diseases;2024-06

4. Bifunctional antibiotic hybrids: A review of clinical candidates;Frontiers in Pharmacology;2023-06-12

5. Antibiotics in the clinical pipeline as of December 2022;The Journal of Antibiotics;2023-06-08